INCY logo

Incyte Corporation

INCY
Healthcare|Biotechnology|US
$119.65
+1.64 (+1.39%)
DCF Value
$113.08
Tangible Book / Share
$26.60
Graham Number
$35.21
Cash / Share
$18.97

Analyst Consensus

Buy45 analysts
Strong Buy
0
Buy
24
Hold
20
Sell
1
Strong Sell
0
Consensus Target
$137.67
Implied Upside
+15.1%
Low Target
$104.00
High Target
$157.00

Price Target Trend

Last Month
$143.00
5 targets · +20% vs price
Last Quarter
$137.58
12 targets · +15% vs price
Last Year
$122.36
47 targets · +2% vs price
All Time
$107.26
81 targets · -10% vs price

Rating Trend

Dec 25
12 buy · 12 hold · 2 sell
Jan 26
12 buy · 12 hold · 2 sell
Feb 26
12 buy · 12 hold · 2 sell
Mar 26
12 buy · 13 hold · 3 sell
Apr 26
11 buy · 13 hold · 2 sell
May 26
11 buy · 15 hold · 2 sell
Jun 26
11 buy · 15 hold · 3 sell
Jul 26
11 buy · 15 hold · 1 sell
Aug 26
12 buy · 15 hold · 1 sell
Sep 26
12 buy · 15 hold · 1 sell
Oct 26
13 buy · 15 hold · 2 sell
Nov 26
13 buy · 14 hold · 2 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Oct 30, 2026UBS$152.00(+30%)$116.80StreetInsider
Oct 30, 2026OppenheimerJay Olson$144.00(+23%)$116.80StreetInsider
Oct 27, 2026Oppenheimer$152.00(+34%)$113.31StreetInsider
Oct 16, 2026Raymond James$152.00(+34%)$113.27StreetInsider
Oct 14, 2026Truist FinancialSrikripa Devarakonda$115.00(+3%)$111.44TheFly
Oct 8, 2026RBC Capital$114.00(+2%)$111.78TheFly
Oct 5, 2026UBSAshwani Verma$127.00(+12%)$113.03StreetInsider
Oct 5, 2026Stifel NicolausStephen Willey$157.00(+36%)$115.30StreetInsider
Sep 28, 2026H.C. WainwrightMitchell Kapoor$152.00(+23%)$123.89StreetInsider
Aug 20, 2026Canaccord Genuity$152.00(+18%)$128.47TheFly
Aug 17, 2026Piper SandlerAllison Bratzel$130.00(+8%)$120.16TheFly
Aug 13, 2026Bernstein$104.00(-14%)$120.77TheFly
Aug 3, 2026Leerink PartnersAndrew Berens$155.00(+30%)$119.52TheFly
Jul 29, 2026RBC CapitalBrian Abrahams$109.00(-14%)$126.69TheFly
Jul 29, 2026BMO Capital$130.00(+1%)$128.83TheFly
Jul 29, 2026GuggenheimWhitney Ljem$150.00(+15%)$129.93StreetInsider
Jul 29, 2026Morgan Stanley$119.00(-8%)$129.93TheFly
Jul 29, 2026H.C. Wainwright$150.00(+15%)$129.93TheFly
Jul 29, 2026Barclays$139.00(+7%)$129.93TheFly
Jul 28, 2026Stifel NicolausStephen Willey$145.00(+11%)$130.08TheFly

Recent Rating Actions

FirmActionRatingDate
Leerink PartnersmaintainOutperformNov 5, 2026
BernsteinmaintainMarket PerformNov 2, 2026
RBC CapitalmaintainSector PerformOct 30, 2026
Wells FargomaintainEqual WeightOct 30, 2026
OppenheimerupgradePerform →OutperformOct 30, 2026
Evercore ISI GroupmaintainIn LineOct 30, 2026
BarclaysmaintainOverweightOct 30, 2026
TD CowenmaintainBuyOct 21, 2026
Truist SecuritiesmaintainHoldOct 14, 2026
HC Wainwright & Co.maintainBuyOct 13, 2026
RBC CapitalmaintainSector PerformOct 8, 2026
StifelmaintainBuyOct 5, 2026
Wells FargomaintainEqual WeightOct 1, 2026
HC Wainwright & Co.maintainBuySep 28, 2026
JP MorganmaintainNeutralSep 28, 2026
RBC CapitalmaintainSector PerformSep 22, 2026
HC Wainwright & Co.maintainBuyAug 20, 2026
Piper SandlermaintainOverweightAug 17, 2026
MizuhomaintainOutperformAug 4, 2026
HC Wainwright & Co.maintainBuyAug 3, 2026
Leerink PartnersmaintainOutperformAug 3, 2026
BarclaysmaintainOverweightJul 29, 2026
BMO CapitalmaintainMarket PerformJul 29, 2026
GuggenheimmaintainBuyJul 29, 2026
RBC CapitalmaintainSector PerformJul 29, 2026

Earnings History

Next report: Feb 9, 2027 · EPS est. $1.90
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 29, 2026$-3.60$-3.93$1.56B$1.46B
Jul 28, 2026$3.09$2.15$1.67B$1.50B
Apr 28, 2026$1.81$1.34$1.27B$1.22B
Feb 10, 2026$1.80$1.90$1.51B$1.35B
Oct 28, 2025$2.26$1.66$1.37B$1.35B
Jul 29, 2025$1.57$1.39$1.22B$1.26B
Apr 29, 2025$1.16$1.01$1.05B$1.15B
Feb 10, 2025$1.43$1.57$1.18B$1.00B

News

2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers. “It is our honor to reco.

Nov 6, 2026businesswire.com
Incyte Corporation $INCY Shares Newly Purchased by Compass Financial Management LLC

Compass Financial Management LLC bought a new position in shares of Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,594 shares of the biopharmaceutical company's stock, valued at approximately $2,378,000. Other hedge

Nov 5, 2026defenseworld.net
Aware Super Pty Ltd as trustee of Aware Super Sells 13,693 Shares of Incyte Corporation $INCY

Aware Super Pty Ltd as trustee of Aware Super lowered its position in Incyte Corporation (NASDAQ: INCY) by 4.5% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 293,117 shares of the biopharmaceutical company's stock after selling 13,693 shares during the

Nov 3, 2026defenseworld.net
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.

Pre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.

Oct 30, 2026247wallst.com
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Oct 30, 2026benzinga.com
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap

I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net sales rose 14% year-over-year; Opzelura and hematology/oncology guidance increased, while Jakafi guidance remains unchanged.

Oct 30, 2026seekingalpha.com
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.

Oct 29, 2026zacks.com
Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript

Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript

Oct 29, 2026seekingalpha.com
What Incyte (INCY) Said on Its Q3 Earnings Call

Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncology products, and total net sales while outlining progress across several late-stage pipeline programs.

Oct 29, 2026marketbeat.com
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Oct 29, 2026zacks.com
Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.

Oct 29, 2026zacks.com
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.

Oct 29, 2026businesswire.com
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Oct 27, 2026seekingalpha.com
Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers

Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KRAS G12D-targeted small molecule known as “'734.”

Oct 26, 2026marketbeat.com
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.

Oct 26, 2026zacks.com
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.

Oct 26, 2026businesswire.com
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

[url="]Genmab A/S[/url] (Nasdaq: GMAB) and [url="]Incyte[/url] (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's

Oct 24, 2026gurufocus.com
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte's investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi.

Oct 24, 2026businesswire.com
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.

Oct 24, 2026businesswire.com
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte's investigational, potent and se

Oct 24, 2026gurufocus.com